Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 16, 2019
Reporting Period: Event-based disclosure for September 16, 2019.
Business Context: The Company is an emerging growth company incorporated in Nevada, trading on NASDAQ under the symbol "INMB". This filing serves as a Regulation FD disclosure regarding upcoming executive presentations.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes or operational updates were reported in this filing. The document solely announces a scheduled corporate event.
Guidance, Outlook, and Management Commentary
- Upcoming Event: Co-Founder and CEO RJ Tesi, M.D., and Co-Founder and Chief Scientific Officer Mark Lowdell, Ph.D., are scheduled to present at the first ever Targeting Innate Immunity Congress.
- Event Details: The congress will take place in Cambridge, Massachusetts, from September 23, 2019, through September 25, 2019.
- Exhibit Status: The press release detailing this event is furnished as Exhibit 99.1 but is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the content of the press release furnished as Exhibit 99.1 for specific details on the presentation topics.
- Confirm the Company's status as an emerging growth company and its implications for financial reporting standards.
- Review subsequent filings (e.g., 10-Q or 10-K) for actual financial performance data, as this 8-K contains no financial metrics.